Clinical Scorecard: Dose Adjustments of Beta-lactam Antibiotics in Critically Ill Patients Experiencing Acute Kidney Injury: A Scoping Review
At a Glance
Category
Detail
Condition
Acute kidney injury (AKI) in critically ill patients
Key Mechanisms
AKI alters renal clearance affecting beta-lactam antibiotic elimination; beta-lactams are primarily renally cleared and dosing is often adjusted based on kidney function estimates
Target Population
Critically ill adult patients with AKI receiving beta-lactam antibiotics
Care Setting
Intensive care unit (ICU)
Key Highlights
AKI incidence in ICU patients ranges from 20 to 75%, with sepsis as a common cause.
Beta-lactam antibiotics have a broad therapeutic window and are frequently underdosed due to unreliable kidney function estimates in critical illness.
Early dose reductions based on AKI may be unnecessary or harmful given the transient nature of AKI and delayed serum creatinine changes.
Guideline-Based Recommendations
Diagnosis
Use KDIGO 2012 criteria based on serum creatinine and urine output to classify AKI severity.
Recognize that serum creatinine is a delayed and imprecise marker of renal function in critically ill patients.
Management
Consider postponing beta-lactam dose reductions until 48 hours after therapy initiation to better assess renal function trajectory.
Avoid initial dose reductions in patients with rapidly reversible or transient AKI to prevent underdosing.
Adjust dosing cautiously in AKI subtypes, e.g., hypovolemic AKI may require aggressive fluid resuscitation affecting antibiotic concentrations.
Monitoring & Follow-up
Monitor pharmacodynamic target attainment especially within the first 48 hours of antibiotic therapy.
Assess clinical outcomes including mortality, treatment failure, and adverse events to guide dosing adjustments.
Risks
Risk of toxicity is low with beta-lactams due to broad therapeutic window, supporting delayed dose reduction.
Underdosing due to premature dose reductions may increase mortality risk in critically ill patients with infections.
Patient & Prescribing Data
Critically ill adults with AKI receiving beta-lactam antibiotics in ICU
Pharmacodynamic targets are often not achieved with early dose reductions; dosing based on chronic kidney disease models may not be appropriate for AKI; early dose reductions may compromise infection control.
Clinical Best Practices
Delay beta-lactam dose reductions until renal function trajectory is clearer, typically after 48 hours.
Use clinical judgment considering AKI etiology and dynamics rather than relying solely on serum creatinine.
Prioritize achieving pharmacodynamic targets in the critical first 48 hours of infection treatment.
Recognize limitations of eGFR and creatinine-based dosing adjustments in critically ill patients.
Incorporate multidisciplinary review including infectious disease and nephrology expertise for dosing decisions.
